These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17512431)

  • 1. New generation of molecular prognostic and predictive tests for breast cancer.
    Pusztai L; Cristofanilli M; Paik S
    Semin Oncol; 2007 Apr; 34(2 Suppl 3):S10-6. PubMed ID: 17512431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular classification of breast cancer: limitations and potential.
    Pusztai L; Mazouni C; Anderson K; Wu Y; Symmans WF
    Oncologist; 2006 Sep; 11(8):868-77. PubMed ID: 16951390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
    Correa Geyer F; Reis-Filho JS
    Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response.
    Loi S; Piccart M; Sotiriou C
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):187-94. PubMed ID: 17088071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
    Huber KE; Carey LA; Wazer DE
    Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling: decoding breast cancer.
    de Snoo F; Bender R; Glas A; Rutgers E
    Surg Oncol; 2009 Dec; 18(4):366-78. PubMed ID: 19879448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
    Brenton JD; Carey LA; Ahmed AA; Caldas C
    J Clin Oncol; 2005 Oct; 23(29):7350-60. PubMed ID: 16145060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling in breast cancer: towards individualising patient management.
    Murphy N; Millar E; Lee CS
    Pathology; 2005 Aug; 37(4):271-7. PubMed ID: 16194824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State of the science: molecular classifications of breast cancer for clinical diagnostics.
    Robison JE; Perreard L; Bernard PS
    Clin Biochem; 2004 Jul; 37(7):572-8. PubMed ID: 15234238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New molecular classifications of breast cancer.
    Cianfrocca M; Gradishar W
    CA Cancer J Clin; 2009; 59(5):303-13. PubMed ID: 19729680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer.
    Calabrò A; Beissbarth T; Kuner R; Stojanov M; Benner A; Asslaber M; Ploner F; Zatloukal K; Samonigg H; Poustka A; Sültmann H
    Breast Cancer Res Treat; 2009 Jul; 116(1):69-77. PubMed ID: 18592372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers of breast axillary lymph node metastasis.
    Cavalli LR
    Expert Rev Mol Diagn; 2009 Jul; 9(5):441-54. PubMed ID: 19580429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
    Loi S
    Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.